Akari Therapeutics Plc (NASDAQ:AKTX) said its research has been selected for presentation at the American Association for Cancer Research (AACR) Annual Meeting 2026, one of the leading global conferences for cancer research. The company’s abstract will be featured as a poster presentation during the event, which will take place April 17–22, 2026.
The presentation will focus on the scientific rationale behind the development of a differentiated antibody-drug conjugate (ADC) targeting the Trop2 receptor in solid tumors, including bladder, lung and breast cancers.
Presentation details
The poster will be presented as part of the conference’s Experimental and Molecular Therapeutics program under the session titled “Targeting Cell Surface Vulnerabilities to Overcome Therapeutic Resistance.”
- Title: Rationale for the development of a differentiated Trop2 ADC in solid tumors of the bladder, lung, and breast
- Poster Number: 3179
- Poster Board Number: 14
- Session Category: Experimental and Molecular Therapeutics
- Session Date and Time: Monday, April 20, 2026 | 2:00 PM – 5:00 PM PT
- Location: Poster Section 19
Following the presentation, the poster will be made available on the Posters & Publications section of Akari’s website after 5:00 PM PT on April 20, 2026.
Company representatives will also be available to meet with conference attendees during the event.
Focus on next-generation ADC technology
Akari Therapeutics is developing next-generation antibody-drug conjugates designed to deliver targeted cancer therapies using a proprietary RNA splice-modulating payload known as PH1.
The company’s lead candidate, AKTX-101, targets the Trop2 receptor found on the surface of certain cancer cells. Using a proprietary linker technology, the drug is designed to deliver the PH1 payload directly into tumor cells while limiting off-target effects.
Unlike many current ADC therapies that rely on tubulin inhibitors or DNA-damaging agents, PH1 works by modulating RNA splicing within cancer cells. Preclinical studies suggest this mechanism can disrupt tumor cell survival while also activating components of the immune system, potentially producing durable anti-tumor responses.
Animal model research has shown that AKTX-101 may improve survival compared with ADCs that use more traditional payloads. The therapy may also work synergistically with checkpoint inhibitors and has demonstrated activity both as a standalone treatment and in combination with immunotherapies.
The PH1 payload has also shown preclinical activity against tumors driven by several oncogenic mutations, including K-RAS G12V, BRAF G466V, AR-V7 and FGFR3 fusions.
Akari has begun investigational new drug (IND)-enabling studies for AKTX-101 and is targeting the start of its first-in-human clinical trial in late 2026 or early 2027.
Additional pipeline development
Alongside AKTX-101, the company is also advancing AKTX-102, another antibody-drug conjugate designed to target CEACAM5 (carcinoembryonic antigen-related cell adhesion molecule-5), a tumor antigen commonly expressed across multiple solid tumor types.
AKTX-102 also uses Akari’s PH1 spliceosome-modulating payload and proprietary antibody platform, with the aim of improving tumor targeting while enhancing immune activation.
Akari Therapeutics is a clinical-stage oncology biotechnology company focused on developing targeted cancer treatments using its ADC discovery platform, which allows the company to design and optimize antibody-drug conjugates for a range of tumor antigens.